Continuous infusion of monoclonal antibody-purified factor VIII.
Continuous intravenous infusion of wet and dry heat treated factor VIII products has been shown to be an effective, safe, and convenient alternative to pulse-dose therapy for the treatment of patients with hemophilia. We have used 12-hr, single-bottle continuous infusion of a factor VIII product purified from plasma sources by the use of monoclonal antibodies (Monoclate; Rorer Pharmaceutical Company) for the treatment of four bleeding episodes in three patients with severe hemophilia A. Patients required 2.1 U/kg/hr to attain an in vivo factor VIII level of 50 U/dl. Clinical hemostasis was achieved for all treatment episodes and no untoward effects of therapy were noted. Stability of the factor VIII:C levels in the product in vitro was also demonstrated. We conclude from this preliminary data that continuous infusion of factor VIII products purified by monoclonal antibody technology is a safe, effective, and practical approach to the treatment of patients with hemophilia A.
Weinstein
R E
RE
Comprehensive Hemophilia Treatment Center, University of Connecticut School of Medicine, Farmington.
Bona
R D
RD
Rickles
F R
FR
D000911:Antibodies, Monoclonal / Q000032:analysis / Q000276:immunology; D005169:Factor VIII / Q000008:administration & dosage* / Q000276:immunology / Q000302:isolation & purification / Q000627:therapeutic use; D006467:Hemophilia A / Q000188:drug therapy; D006801:Humans; D007262:Infusions, Intravenous
D000911:Antibodies, Monoclonal; D005169:Factor VIII